Paid Clinical Trials Morgantown
Discover 280 paid clinical trials in Morgantown, West Virginia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Axatilimab & CorticosteroidsA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Sponsor:
Incyte Corporation
Location:
Code:
NCT06585774
Conditions
Chronic Graft-versus-host-disease
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
INCA034176
Placebo
Corticosteroids
Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
Sponsor:
SWOG Cancer Research Network
Location:
Code:
NCT04071457
Conditions
Multiple Myeloma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Lenalidomide
Daratumumab/rHuPH20
CamizestrantAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Sponsor:
AstraZeneca
Location:
Code:
NCT05952557
Conditions
Breast Cancer, Early Breast Cancer
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Camizestrant
Tamoxifen
Anastrozole
Letrozole
Exemestane
ONC201ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Sponsor:
Chimerix
Location:
Code:
NCT05580562
Conditions
H3 K27M
Glioma
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Dordaviprone (ONC201)
Dordaviprone (ONC201) + Placebo
Placebo
Observational StudyA Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Sponsor:
Target PharmaSolutions, Inc.
Location:
Code:
NCT02815891
Conditions
Nonalcoholic Fatty Liver
Nonalcoholic Steatohepatitis
Eligibility Criteria
Sex: All
Age: 2+
Healthy Volunteers: Not accepted
Fianlimab & CemiplimabA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05608291
Conditions
Melanoma
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Fianlimab
Cemiplimab
Pembrolizumab
Placebo
MagicTouchMagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
Sponsor:
Concept Medical Inc.
Location:
Code:
NCT05908331
Conditions
In-Stent Restenosis
Cardiovascular Diseases
Coronary Artery Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Sirolimus Drug Coated Balloon
Plan balloon Angioplasty (POBA)
Intra-operative Radiotherapy & External Beam RadiotherapyA Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
Sponsor:
University College, London
Location:
Code:
NCT01792726
Conditions
Early Breast Cancer
Eligibility Criteria
Sex: Female
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Boost to the tumour bed
DonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Sponsor:
Eli Lilly and Company
Location:
Code:
NCT05026866
Conditions
Alzheimer Disease
Eligibility Criteria
Sex: All
Age: 65 - 70+
Healthy Volunteers: Not accepted
Interventions
Donanemab
Placebo